- Home
- ESLA vs BDSX Comparison
ESLA vs BDSX Comparison
Compare ESLA & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- BDSX
- Stock Information
- Founded
- ESLA 2021
- BDSX 2005
- Country
- ESLA United States
- BDSX United States
- Employees
- ESLA N/A
- BDSX N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- BDSX Precision Instruments
- Sector
- ESLA Health Care
- BDSX Health Care
- Exchange
- ESLA Nasdaq
- BDSX Nasdaq
- Market Cap
- ESLA 48.9M
- BDSX 53.0M
- IPO Year
- ESLA N/A
- BDSX 2020
- Fundamental
- Price
- ESLA $2.57
- BDSX $6.47
- Analyst Decision
- ESLA Strong Buy
- BDSX Strong Buy
- Analyst Count
- ESLA 1
- BDSX 5
- Target Price
- ESLA $16.00
- BDSX $32.50
- AVG Volume (30 Days)
- ESLA 358.0K
- BDSX 278.8K
- Earning Date
- ESLA 11-20-2025
- BDSX 11-03-2025
- Dividend Yield
- ESLA N/A
- BDSX N/A
- EPS Growth
- ESLA N/A
- BDSX N/A
- EPS
- ESLA N/A
- BDSX N/A
- Revenue
- ESLA N/A
- BDSX $76,556,000.00
- Revenue This Year
- ESLA N/A
- BDSX $18.78
- Revenue Next Year
- ESLA N/A
- BDSX $26.42
- P/E Ratio
- ESLA N/A
- BDSX N/A
- Revenue Growth
- ESLA N/A
- BDSX 25.70
- 52 Week Low
- ESLA $0.63
- BDSX $3.44
- 52 Week High
- ESLA $2.60
- BDSX $34.39
- Technical
- Relative Strength Index (RSI)
- ESLA 75.76
- BDSX 50.38
- Support Level
- ESLA $2.13
- BDSX $6.22
- Resistance Level
- ESLA $2.55
- BDSX $7.00
- Average True Range (ATR)
- ESLA 0.31
- BDSX 0.60
- MACD
- ESLA 0.06
- BDSX -0.24
- Stochastic Oscillator
- ESLA 90.63
- BDSX 32.12
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.